Targeting AMP‐activated kinase impacts hepatocellular cancer stem cells induced by long‐term treatment with sorafenib

Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. HCC treatment is hindered by the frequent emergence of chemoresistance to the multikinase inhibitor sorafenib, which has been related to the presence of cancer stem cells (CSCs) that self‐renew and often escape ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Bort, Alicia, Sánchez, Belén G., Mateos‐Gómez, Pedro A., Vara‐Ciruelos, Diana, Rodríguez‐Henche, Nieves, Díaz‐Laviada, Inés
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487713/
https://www.ncbi.nlm.nih.gov/pubmed/30959553
http://dx.doi.org/10.1002/1878-0261.12488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487713/
https://www.ncbi.nlm.nih.gov/pubmed/30959553
http://dx.doi.org/10.1002/1878-0261.12488

Ejemplares similares